Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis.

ABSTRACT:

Introduction

Although there are a number of neoadjuvant immunotherapy combinations that can be applied to the treatment of perioperative non-small cell lung cancer patients, the optimal treatment combination strategy has not yet been determined.

Methods

We searched PubMed, EMBASE, Cochrane Library, ClinicalTrials.go and randomised controlled trials (RCTs) from major international conferences for literature related to neoadjuvant immunotherapy combinations published as first-line treatment options for non-small cell lung cancer from the start of the library to 20 February 2024, and performed a systematic review and network meta-analysis.

Results

We analyzed nine studies involving 3431 patients, including eight perioperative neoadjuvant immunotherapy combinations for no

SUBMITTER: Wang L 

PROVIDER: S-EPMC11781062 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature